Compare McKesson Corporation (MCK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs BIO-TECHNE Corp — how do they compare? McKesson Corporation trades at $930 (market cap $106.14B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: McKesson Corporation is far larger — about 9.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and BIO-TECHNE Corp for 63 Days on average.
| MCK | TECH | |
|---|---|---|
Market Cap | $106.14B | $11.37B |
Volume | 794,405 | 3,153,511 |
Sector | Health | Health |
52-Week High | $995.69 | $72.61 |
52-Week Low | $725.17 | $43.31 |
Typical Hold Time | 74 Days | 63 Days |
Enterprise Value | $112.67B | $11.40B |
Dividend Yield | 0.41% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
